X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA STERLING BIOTECH ALEMBIC PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 28.1 -1.8 - View Chart
P/BV x 6.4 0.1 9,103.1% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALEMBIC PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
STERLING BIOTECH
Dec-13
ALEMBIC PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs79211 7,540.0%   
Low Rs4433 13,029.4%   
Sales per share (Unadj.) Rs167.026.8 623.1%  
Earnings per share (Unadj.) Rs38.2-15.0 -255.1%  
Cash flow per share (Unadj.) Rs42.0-5.5 -768.7%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.954.9 154.7%  
Shares outstanding (eoy) m188.52267.87 70.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.70.3 1,425.7%   
Avg P/E ratio x16.2-0.5 -3,481.4%  
P/CF ratio (eoy) x14.7-1.3 -1,155.5%  
Price / Book Value ratio x7.30.1 5,742.1%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3831,862 6,251.4%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m4,214547 770.6%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m31,4877,181 438.5%  
Other income Rs m5543 129.3%   
Total revenues Rs m31,5427,223 436.7%   
Gross profit Rs m10,060947 1,062.4%  
Depreciation Rs m7222,543 28.4%   
Interest Rs m374,377 0.8%   
Profit before tax Rs m9,356-5,931 -157.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,160-1,924 -112.3%   
Profit after tax Rs m7,194-4,007 -179.6%  
Gross profit margin %31.913.2 242.3%  
Effective tax rate %23.132.4 71.2%   
Net profit margin %22.8-55.8 -41.0%  
BALANCE SHEET DATA
Current assets Rs m15,06614,335 105.1%   
Current liabilities Rs m7,67449,809 15.4%   
Net working cap to sales %23.5-494.0 -4.8%  
Current ratio x2.00.3 682.1%  
Inventory Days Days67403 16.6%  
Debtors Days Days41171 23.8%  
Net fixed assets Rs m8,23755,432 14.9%   
Share capital Rs m377268 140.7%   
"Free" reserves Rs m15,41613,935 110.6%   
Net worth Rs m16,00514,701 108.9%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m24,59473,988 33.2%  
Interest coverage x255.2-0.4 -71,906.2%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.1 1,319.2%   
Return on assets %29.40.5 5,870.0%  
Return on equity %44.9-27.3 -164.9%  
Return on capital %58.7-6.4 -913.1%  
Exports to sales %55.725.9 215.2%   
Imports to sales %10.40.2 6,136.8%   
Exports (fob) Rs m17,5511,860 943.7%   
Imports (cif) Rs m3,28312 26,909.8%   
Fx inflow Rs m17,8111,860 957.7%   
Fx outflow Rs m5,31825 21,366.0%   
Net fx Rs m12,4931,835 680.8%   
CASH FLOW
From Operations Rs m9,3041,719 541.3%  
From Investments Rs m-3,105-3,148 98.6%  
From Financial Activity Rs m-1,9591,426 -137.4%  
Net Cashflow Rs m4,240-3 -124,705.9%  

Share Holding

Indian Promoters % 74.1 33.9 218.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.0 -  
FIIs % 9.1 9.9 91.9%  
ADR/GDR % 0.0 16.9 -  
Free float % 13.9 39.3 35.4%  
Shareholders   49,328 21,482 229.6%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  PLETHICO PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS